NeuroSense Therapeutics NRSN
NASDAQ NRSN
$6.62 +0.27 (+4.25%)
At close: Sep 21, 2026 · 4:00 PM EDT

NeuroSense Therapeutics (NRSN) Non Operating Interest Expenses (2021 - 2023)

NeuroSense Therapeutics' (NRSN) quarterly Non Operating Interest Expenses came in at $2.7 million in Q4 2023, up 2638.14% year-over-year from $97000.0 in Q4 2022, and up 22233.33% quarter-over-quarter from -$12000.0 in Q3 2023.

Analysis

NeuroSense Therapeutics (NRSN) Non Operating Interest Expenses (2021 - 2023) Analysis & Trends

NeuroSense Therapeutics has disclosed Non Operating Interest Expenses across 3 years of filings, most recently posting $2.7 million for Q4 2023.

  • In Q4 2023, Non Operating Interest Expenses rose 2638.14% year-over-year to $2.7 million; the TTM figure through Dec 2023 stood at $448000.0 (up 1444.83% YoY), while the FY2025 annual figure was $53000.0, down 85.11% from the prior year.
  • Non Operating Interest Expenses came in at $2.7 million for Q4 2023 at NeuroSense Therapeutics, up from -$12000.0 in the prior quarter.
  • In the past five years, Non Operating Interest Expenses ranged from a high of $2.7 million in Q4 2023 to a low of -$1.9 million in Q2 2023.
  • Average Non Operating Interest Expenses over 3 years is -$78666.7, with a median of -$23000.0 recorded in 2022.
  • The largest YoY upside for Non Operating Interest Expenses was 2638.14% in 2023 against a maximum downside of 5288.57% in 2023.
  • Over 3 years, Non Operating Interest Expenses stood at -$1.2 million in 2021, then surged by 108.19% to $97000.0 in 2022, then jumped by 2638.14% to $2.7 million in 2023.
  • Per Business Quant data, the three most recent Non Operating Interest Expenses figures were $2.7 million in Q4 2023, -$12000.0 in Q3 2023, and -$1.9 million in Q2 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Amgen 208.48 Bn 194.49 Bn 7.24 Bn 673.00 Mn
2 Gilead Sciences 186.29 Bn 183.02 Bn 6.22 Bn 247.00 Mn
3 Vertex Pharmaceuticals 128.79 Bn 120.93 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 80.66 Bn 72.67 Bn 3.93 Bn 11.00 Mn
5 Moderna 61.46 Bn 56.32 Bn 52.00 Mn -
6 Argenx Se 61.28 Bn 56.10 Bn 1.37 Bn -1.00 Mn
7 Alnylam Pharmaceuticals 32.04 Bn 28.73 Bn 992.69 Mn 82.05 Mn
8 Biogen 31.84 Bn 30.56 Bn 1.96 Bn -
9 Roivant Sciences 28.74 Bn 29.43 Bn 1.16 Mn -
10 NeuroSense Therapeutics 8.09 Mn 7.88 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 2.66 Mn
Sep 30, 2023 -12,000.00
Jun 30, 2023 -1.89 Mn
Mar 31, 2023 -310,000.00
Dec 31, 2022 97,000.00
Sep 30, 2022 -10,000.00
Jun 30, 2022 -35,000.00
Mar 31, 2022 -23,000.00
Dec 31, 2021 -1.19 Mn
API Access

NeuroSense Therapeutics Non Operating Interest Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-interest-expenses&ticker=NRSN&period=max&api_key=YOUR_API_KEY